

HMR acquires volunteer recruitment services of InCROM Europe

Hammersmith Medicines Research (HMR) is an independent phase 1 CRO with a new 100-bed clinical pharmacology unit in North West London. Since 2002, HMR has successfully completed serial ‘bridging’ studies in healthy Japanese, Korean and Chinese subjects, to help sponsors to satisfy the Japanese regulatory authorities. HMR’s dedicated team of bilingual Japanese nurses and support staff have years of experience of bridging studies, including:

- bioequivalence studies of new products not yet marketed in Japan
- studies that can’t be done in Japan, such as a study of an opioid
- studies with ‘add-on’ cohorts of Japanese subjects for large, complex, first-in-man single- and repeat-dose trials in Caucasians

For 8 years HMR has worked with InCROM Europe – a specialist Japanese volunteer recruitment company, with a big database of Japanese volunteers. About 40,000 Japanese people live in the UK, and the largest Japanese community in London is near HMR.

This month HMR acquired the Japanese volunteer recruitment services of InCROM Europe. Acquiring InCROM’s capability enables HMR to bring recruitment of Japanese volunteers in-house, and to strengthen links with InCROM Japan.

HMR’s exceptional reputation for phase 1 trials, coupled with InCROM Europe’s expertise in finding Japanese subjects, makes them the ideal choice for bridging studies.

We have spacious new premises with 100 beds, resuscitation team, CAP-accredited laboratory, pharmacy and radiopharmacy, and MHRA Supplementary Accreditation. There are separate facilities with TV room, computer games, DVDs, comics and books for Japanese bridging studies. And our kitchen can prepare Japanese meals. Japanese subjects tell us they like doing studies at HMR!

Central monitoring and ECG telemetry on all beds

